Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

18 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-003008-30-GB (EUCTR)	01/07/2020	17/05/2018	Simvastatin in Secondary Progressive Multiple Sclerosis	A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage - MS-OPT Version 1.3 dated 23/05/18	Multiple Sclerosis (Secondary Progressive) MedDRA version: 20.0;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets Product Code: Not applicable INN or Proposed INN: Simvastatin	University College London	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	United Kingdom
2	EUCTR2019-003127-38-NL (EUCTR)	09/04/2020	09/04/2020	Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients treated with ocrelizumab and natalizumab.	Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial. - SIMSON trial	Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Simvastatin INN or Proposed INN: SIMVASTATIN Other descriptive name: Simvastatine	VUmc Neurology Department	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Netherlands
3	NCT04178980 (ClinicalTrials.gov)	January 1, 2020	25/11/2019	Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis	Double-blinded, Randomized Controlled Trial of Simvastatin Use As Adjuvant Therapy in Relapsing-Remitting Multiple Sclerosis	Simvastatin Multiple Sclerosis	Drug: Simvastatin in relapsing remitting multiple sclerosis	Assiut University	NULL	Not yet recruiting	18 Years	65 Years	All	60	Phase 1	NULL
4	NCT03896217 (ClinicalTrials.gov)	May 16, 2019	26/10/2018	Simvastatin in Secondary Progressive Multiple Sclerosis	A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage	Secondary Progressive Multiple Sclerosis	Drug: Simvastatin	University College, London	MS Society	Recruiting	18 Years	65 Years	All	40	Phase 2	United Kingdom
5	NCT03387670 (ClinicalTrials.gov)	March 28, 2018	28/11/2017	Multiple Sclerosis-Simvastatin Trial 2	A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability	Secondary Progressive Multiple Sclerosis (SPMS)	Drug: Simvastatin;Drug: Placebo	University College, London	University of Edinburgh;Queen Mary University of London;London School of Hygiene and Tropical Medicine;University of Leeds;The Leeds Teaching Hospitals NHS Trust;Imperial College Healthcare NHS Trust	Recruiting	25 Years	65 Years	All	1180	Phase 3	Ireland;United Kingdom
6	EUCTR2017-003328-56-GB (EUCTR)	19/12/2017	31/10/2017	MS-STAT2 - Multiple Sclerosis – Simvastatin Trial 2	A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability - MS-STAT2	Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets INN or Proposed INN: Simvastatin Trade Name: Simvastatine Sandoz 40 mg filmomhulde tabletten Product Name: Simvastatine Sandoz 40 mg filmomhulde tabletten INN or Proposed INN: Simvastatin Trade Name: SimvaHEXAL® 40 mg Filmtabletten Product Name: SimvaHEXAL® 40 mg Filmtabletten INN or Proposed INN: Simvastatin Trade Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG Product Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG INN or Proposed INN: Simvastatin Trade Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película Product Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película INN or Proposed INN: Simvastatin Trade Name: Sivatin 40 mg film-coated tablets Product Name: Sivatin 40 mg film-coated tablets INN or Proposed INN: Simvastatin Trade Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten Product Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten INN or Proposed INN: Simvastatin	University College London Comprehensive Clinical Trials Unit	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1180	Phase 3	United Kingdom
7	EUCTR2006-001827-21-DK (EUCTR)	06/03/2009	15/01/2009	A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone for at least 3 monthsStudy Phase: III - Simvastatin/Copaxone	A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone for at least 3 monthsStudy Phase: III - Simvastatin/Copaxone	Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: Simvastatin Trade Name: Copaxone Product Name: Glatiramer acetate	Glostrup Hospital, Dep. of Neurology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Denmark
8	NCT00429442 (ClinicalTrials.gov)	March 2008	30/1/2007	Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis	A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in Patients Treated With Copaxone for at Least 3 Months	Relapsing Remitting Multiple Sclerosis	Drug: Simvastatin;Drug: placebo	Anna Tsakiri	Sanofi	Withdrawn	18 Years	60 Years	Both	0	Phase 3	Denmark
9	NCT00647348 (ClinicalTrials.gov)	January 2008	26/3/2008	Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis	A Phase II Randomised, Placebo-controlled Clinical Trial of Simvastatin in Patients With Secondary Progressive Multiple Sclerosis.	Secondary Progressive Multiple Sclerosis	Drug: Simvastatin;Drug: Placebo	Imperial College London	NULL	Completed	18 Years	65 Years	All	140	Phase 2	United Kingdom
10	EUCTR2006-006347-31-GB (EUCTR)	06/09/2007	07/08/2007	A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis	A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis	Multiple Sclerosis MedDRA version: 9.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive	Product Name: Encapsulated Simvastatin tablets Product Code: MSTC-001 (MS-STAT)	Imperial College London	NULL	Not Recruiting			Female: yes Male: yes	140	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
11	NCT00261326 (ClinicalTrials.gov)	September 2006	2/12/2005	Simvastatin Treatment of Patients With Acute Optic Neuritis	Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial	Optic Neuritis;Multiple Sclerosis	Drug: simvastatin;Drug: placebo	Glostrup University Hospital, Copenhagen	Alpharma ApS	Active, not recruiting	18 Years	59 Years	Both	64	Phase 3	Denmark
12	NCT00492765 (ClinicalTrials.gov)	February 2006	25/6/2007	Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon-beta -1a;Drug: Simvastatin;Drug: Placebo	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	380	Phase 4	Denmark
13	EUCTR2005-003930-16-SE (EUCTR)	19/01/2006	21/11/2005	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclusion criteria. Patients will be recruited from the outpatient clinics of the participating neurological departments among patients who are eligible for treatment with interferon-beta-1a. MedDRA version: 7.0;Level: PT;Classification code 10028425	Product Name: Simvastatin Alternova INN or Proposed INN: Simvastatin	Biogen Idec A/S	NULL	Not Recruiting			Female: yes Male: yes	380		Finland;Sweden
14	EUCTR2005-003930-16-FI (EUCTR)	05/01/2006	29/11/2005	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclusion criteria. Patients will be recruited from the outpatient clinics of the participating neurological departments among patients who have been prescribed treatment with Avonex. MedDRA version: 7.0;Level: PT;Classification code 10028425	Trade Name: Simvastatin Alternova Product Name: Simvastatin Alternova INN or Proposed INN: Simvastatin	Biogen Idec A/S	NULL	Not Recruiting			Female: yes Male: yes	380		Finland;Sweden
15	EUCTR2005-003930-16-DK (EUCTR)	09/12/2005	05/12/2005	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclusion criteria. Patients will be recruited from the outpatient clinics of the participating neurological departments among patients who are eligible for treatment with interferon-beta-1a. MedDRA version: 7.0;Level: PT;Classification code 10028425	Product Name: Simvastatin Alternova INN or Proposed INN: Simvastatin	Biogen Idec A/S	NULL	Not Recruiting			Female: yes Male: yes	380		Finland;Denmark;Sweden
16	NCT00242268 (ClinicalTrials.gov)	October 2005	19/10/2005	A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis		Relapsing Remitting Multiple Sclerosis	Drug: Simvastatin	Alabama Neurology Associates, PC	Biogen Idec	Recruiting	18 Years	55 Years	Both	30	Phase 3	United States
17	NCT00668343 (ClinicalTrials.gov)	April 2005	27/4/2008	Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo		Relapsing Remitting Multiple Sclerosis	Drug: simvastatin;Drug: placebo	Tehran University of Medical Sciences	NULL	Completed	15 Years	60 Years	Both	80	Phase 3	Iran, Islamic Republic of
18	NCT00146068 (ClinicalTrials.gov)	September 2004	1/9/2005	EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis	Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period	Multiple Sclerosis	Drug: Avonex /Zocor	University of North Carolina	NULL	Completed	18 Years	60 Years	Both	30	Phase 4	United States

先頭へ